{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:17:05Z","timestamp":1790709425249,"version":"4.1.0"},"reference-count":41,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Prostate cancer (PCa) is a common disease, with a significant number of patients initially diagnosed with locoregional or distant metastases. This is why it is essential to have imaging tests with sufficient sensitivity and specificity. Given the recognized limitations of traditional imaging methods, PSMA-PET has emerged as a promising tool that may revolutionize the management of PCa. Material and Methods: We conducted a comprehensive literature review from August to October 2023 using databases and a review of key clinical guidelines on the topic, focusing on the sensitivity and specificity of PSMA-PET, its use in detecting lymph node metastases (LNm), its integration into nomograms, its comparison with conventional imaging and current guideline recommendations. Results: After considering the search strategy, as well as the inclusion and exclusion criteria, four articles and five guidelines were particularly considered in this review. Most of them suggest high specificity and limited sensitivity for 68Ga-PSMA-PET, with increased detection rates compared to conventional imaging modalities, especially in high-risk PCa patients. However, it cannot replace an extended pelvic lymph node dissection (ePLND) at this time. Conclusions: Although the enhanced sensitivity and specificity of PSMA-PET relative to conventional imaging modalities offers a more precise evaluation of disease extent, prospective studies demonstrating a survival benefit are currently lacking; therefore, caution is advised when making therapeutic decisions.<\/jats:p>","DOI":"10.3390\/medicina61050924","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T08:41:12Z","timestamp":1747730472000},"page":"924","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) in Initial Staging of Prostate Cancer Patients: The Beginning of a New Era"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0556-3035","authenticated-orcid":false,"given":"Juan","family":"G\u00f3mez Rivas","sequence":"first","affiliation":[{"name":"Department of Urology, Cl\u00ednico San Carlos University Hospital, Institute for Health Research, Universidad Complutense de Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4064-9133","authenticated-orcid":false,"given":"Irene","family":"de la Parra","sequence":"additional","affiliation":[{"name":"Department of Urology, Ram\u00f3n y Cajal University Hospital, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9558-8497","authenticated-orcid":false,"given":"Sarelis","family":"Infante","sequence":"additional","affiliation":[{"name":"Department of Urology, Cl\u00ednico San Carlos University Hospital, Institute for Health Research, Universidad Complutense de Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Iba\u00f1ez","sequence":"additional","affiliation":[{"name":"Department of Urology, Cl\u00ednico San Carlos University Hospital, Institute for Health Research, Universidad Complutense de Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4659-1470","authenticated-orcid":false,"given":"Beatriz","family":"Gutierrez Hidalgo","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital of Canarias, 38320 Tenerife, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Nieves","family":"Cabrera","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicina, Cl\u00ednico San Carlos University Hospital, Institute for Health Research, Universidad Complutense de Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Puente","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cl\u00ednico San Carlos University Hospital, Institute for Health Research, Universidad Complutense de Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Sanmamed","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cl\u00ednico San Carlos University Hospital, Institute for Health Research, Universidad Complutense de Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2978-3187","authenticated-orcid":false,"given":"Luis Enrique","family":"Ortega Polledo","sequence":"additional","affiliation":[{"name":"Department of Urology, Cl\u00ednico San Carlos University Hospital, Institute for Health Research, Universidad Complutense de Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2223-9018","authenticated-orcid":false,"given":"Mar\u00eda Isabel","family":"Galante","sequence":"additional","affiliation":[{"name":"Department of Urology, Cl\u00ednico San Carlos University Hospital, Institute for Health Research, Universidad Complutense de Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6837-7718","authenticated-orcid":false,"given":"Jes\u00fas","family":"Moreno Sierra","sequence":"additional","affiliation":[{"name":"Department of Urology, Cl\u00ednico San Carlos University Hospital, Institute for Health Research, Universidad Complutense de Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Juan, G.R., Laura, F.H., Javier, P.V., Natalia, V.C., Isabel, G.R.M., Enrique, R.G., Jos\u00e9 Luis, S.P., Pablo, A.L., Noelia, S.S., and Roser, V.D. (2022). Where Do We Stand in the Management of Oligometastatic Prostate Cancer? A Comprehensive Review. Cancers, 14.","DOI":"10.3390\/cancers14082017"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Thomas, L., Balmus, C., Ahmadzadehfar, H., Essler, M., Strunk, H., and Bundschuh, R.A. (2017). Assessment of Bone Metastases in Patients with Prostate Cancer-A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET\/CT. Pharmaceuticals, 10.","DOI":"10.3390\/ph10030068"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"proPSMA Study Group Collaborators. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","article-title":"The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer","volume":"42","author":"Avtzi","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","article-title":"Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer","volume":"195","author":"Maurer","year":"2016","journal-title":"J. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bju.13814","article-title":"A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy","volume":"120","author":"Hayen","year":"2017","journal-title":"BJU Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.19.02757","article-title":"Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline","volume":"38","author":"Trabulsi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_13","unstructured":"Sanda, M.G., Chen, R.C., Crispino, T., Freedland, S., Greene, K., Klotz, L.H., Makarov, D.V., Nelson, J.B., Reston, J., and Rodrigues, G. (2024, February 12). C\u00e1ncer de Pr\u00f3stata Cl\u00ednicamente Localizado-CAU. Available online: https:\/\/caunet.org\/news\/cancer-de-prostata-clinicamente-localizado\/."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2022.11.002","article-title":"Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-\/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022","volume":"83","author":"Gillessen","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S1470-2045(08)70203-1","article-title":"MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: A prospective multicohort study","volume":"9","author":"Heesakkers","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/JU.0000000000000531","article-title":"Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography\/Computerized Tomography for Primary Staging of Prostate Cancer","volume":"203","author":"Lavalaye","year":"2020","journal-title":"J. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.eururo.2017.03.049","article-title":"Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer","volume":"72","author":"Gandaglia","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_18","first-page":"19","article-title":"External validation of Memorial Sloan Kettering Cancer Center nomogram and prediction of optimal candidate for lymph node dissection in clinically localized prostate cancer","volume":"73","author":"Milonas","year":"2020","journal-title":"Cent. Eur. J. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eururo.2018.10.012","article-title":"A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies","volume":"75","author":"Gandaglia","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2021.05.006","article-title":"External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: An International Multicenter Study","volume":"80","author":"Meijer","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_22","unstructured":"Brierley, J.D., Gospodarowicz, M.K., and Wittekind, C. (2017). TNM Classification of Malignant Tumors, UICC International Union Against Cancer. [8th ed.]."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"Whittington","year":"1998","journal-title":"JAMA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.euo.2023.05.003","article-title":"Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of the Memorial Sloan Kettering Cancer Center and Briganti Nomograms and Development of a Novel Tool","volume":"6","author":"Gandaglia","year":"2023","journal-title":"Eur. Urol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Dondi, F., Antonelli, A., Suardi, N., Treglia, G., and Bertagna, F. (2024). The Role of PSMA PET Imaging in the Classification of the Risk of Prostate Cancer Patients: A Systematic Review on the Insights to Guide an Active Surveillance Approach. Cancers, 16.","DOI":"10.3390\/cancers16061122"},{"key":"ref_26","unstructured":"FDA (2025, January 13). FDA Approves Second PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-approves-second-psma-targeted-pet-imaging-drug-men-prostate-cancer."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2967\/jnumed.120.252114","article-title":"Safety, biodistribution and radiation dosimetry of 18F-rhPSMA-7.3 in healthy adult volunteers","volume":"62","author":"Tolvanen","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2967\/jnumed.119.234187","article-title":"Head-to-Head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET\/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard","volume":"61","author":"Kuten","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"416.e1","DOI":"10.1016\/j.clgc.2022.11.012","article-title":"YAU Prostate Cancer Working Group. The Changing Face of cN0M0 Prostate Cancer Being Found With pN+ After Surgery in the Contemporary Era: Results of an International European Survey on Disease Management","volume":"21","author":"Sacco","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.euo.2023.08.010","article-title":"Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography\/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters","volume":"7","author":"Mazzone","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00345-018-2182-1","article-title":"68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: A systematic review","volume":"36","author":"Corfield","year":"2018","journal-title":"World J. Urol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1016\/j.eururo.2020.06.022","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guidelines Panel. Prostate-specific Membrane Antigen Positron Emission Tomography Scans Before Curative Treatment: Ready for Prime Time?","volume":"78","author":"Cornford","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2967\/jnumed.121.263262","article-title":"Appropriate use criteria for prostate-specific membrane antigen PET imaging","volume":"63","author":"Jadvar","year":"2022","journal-title":"J Nucl Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00259-020-04974-w","article-title":"Pelvic lymph-node staging with 18F-DCFPyL PET\/CT prior to extended pelvic lymph-node dissection in primary prostate cancer\u2014The SALT trial","volume":"48","author":"Jansen","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","article-title":"Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis","volume":"77","author":"Perera","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.eururo.2023.06.018","article-title":"LIGHTHOUSE Study Group. Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)","volume":"84","author":"Surasi","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.eururo.2023.07.007","article-title":"Prostate-specific Membrane Antigen Imaging Remains True to its Name in Primary Staging of Prostate Cancer: The Time To Characterize its Impact on Clinical Outcomes Is Now","volume":"84","author":"Pouliot","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with 18F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J. Urol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","article-title":"Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase 3 imaging trial","volume":"7","author":"Hope","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.2967\/jnumed.117.198812","article-title":"Seduction by Sensitivity: Reality, Illusion, or Delusion? The Challenge of Assessing Outcomes after PSMA Imaging Selection of Patients for Treatment","volume":"58","author":"Hicks","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41585-022-00670-6","article-title":"Using PSMA imaging for prognostication in localized and advanced prostate cancer","volume":"20","author":"Roberts","year":"2023","journal-title":"Nat. Rev. Urol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/5\/924\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:35:40Z","timestamp":1760031340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/5\/924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["medicina61050924"],"URL":"https:\/\/doi.org\/10.3390\/medicina61050924","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]}}}